Clinical trials: Leukemia, B-Cell, Chronic
B-cell Malignancies
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.
- Trial name
- TITANium (NCT06542250)
- Testing
- AZD5492
- Where
- 31 sites in United States, Australia and 8 more
- Volunteers
- 174 people
- Sponsor
- AstraZeneca
Leukemia Lymphocytic Chronic B-Cell
Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
This is a dose finding study using a 3 + 3 dose escalation and expansion design to determine a Not Tolerated Dose (NTD), Optimal Biological Effect Dose (OBE) and / or Maximum Tolerated Dose (MTD).
- Trial name
- NCT01732861
- Testing
- CC-292, Lenalidomide
- Where
- 11 sites in United States, Austria
- Volunteers
- 20 people
- Sponsor
- Celgene
Lymphoma, Prostate Cancer
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as AMG-479, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Conditions
- Lymphoma, Prostate Cancer, Sarcoma, Small Intestine Cancer
- Trial name
- NCT00562380
- Testing
- ganitumab, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Amgen
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL
This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of ICP-022 versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.
- Trial name
- NCT04578613
- Testing
- ICP-022, Chlorambucil, Rituximab
- Where
- 56 sites in China
- Volunteers
- 218 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
The purpose of this study is to determine the long-term safety of a fixed-dose, daily regimen of PCI-32765 PO in subjects with B cell lymphoma or chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Well-differentiated Lymphocytic Lymphoma, B Cell Lymphoma
- Trial name
- NCT01109069
- Testing
- PCI-32765
- Where
- 16 sites in United States
- Volunteers
- 199 people
- Sponsor
- Pharmacyclics LLC.
Leukemia, Lymphocytic, Chronic
Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)
Multicenter, open-label, study of alvocidib in previously treated chronic lymphocytic leukemia patients. Primary objective is to determine overall response rate.
- Trial name
- NCT00464633
- Testing
- alvocidib
- Where
- 34 sites in United States, Australia and 7 more
- Volunteers
- 165 people
- Sponsor
- Sanofi
Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL)
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
This study will identify the highest dose, and assess the safety, of cerdulatinib (PRT062070) that may be given in participants with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or non-hodgkin…
- Conditions
- Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), T-cell Lymphoma (PTCL and CTCL)
- Trial name
- NCT01994382
- Testing
- Cerdulatinib, Rituximab
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Chronic Lymphocytic Leukemia
Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
This study evaluates the effect of the addition of ublituximab, a novel monoclonal antibody, to ibrutinib compared to ibrutinib alone on antitumor activity, as measured by the overall response rate (ORR = CR [complete response] +…
- Trial name
- GENUINE (NCT02301156)
- Testing
- Ublituximab, Ibrutinib
- Where
- 88 sites in United States, Israel
- Volunteers
- 126 people
- Sponsor
- TG Therapeutics, Inc.
Leukemia
A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
This is an open-label, dose escalation study designed to characterize the safety, tolerability, efficacy, and pharmacokinetics of GNKG168 in patients with B-CLL that has relapsed or is refractory to all prior standard therapy, or…
- Trial name
- NCT01035216
- Testing
- GNKG168
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- SBI Biotech Co., Ltd.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma
The purpose of this study is to evaluate the efficacy and safety of ibrutinib versus rituximab in adult Asia Pacific region patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma…
- Trial name
- NCT01973387
- Testing
- Rituximab, Ibrutinib
- Where
- 26 sites in Australia, China and 2 more
- Volunteers
- 160 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Lymphocytic Leukemia
Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia
The purpose of this study is to determine the recommended dose for the combination of dasatinib and bendamustine in chronic lymphocytic leukemia (CLL).
- Trial name
- NCT00872976
- Testing
- Dasatinib, Combination of Bendamustine + Dasatinib
- Where
- 3 sites in United States
- Sponsor
- Bristol-Myers Squibb
CLL/SLL, NHL
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-760 in patients with previously treated CLL/SLL or NHL
- Conditions
- CLL/SLL, NHL, MCL, MZL
- Trial name
- NCT05176691
- Testing
- HMPL-760
- Where
- 36 sites in United States, Australia and 5 more
- Sponsor
- Hutchmed
Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
The main purpose of this first human study with CC-115 is to assess the safety and action of a new class of experimental drug (dual DNA-PK and TOR kinase inhibitors) in patients with advanced tumors unresponsive to standard…
- Conditions
- Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck, Prostate Cancer, Ewing's Osteosarcoma
- Trial name
- NCT01353625
- Testing
- CC-115
- Where
- 17 sites in United States, France and 2 more
- Volunteers
- 118 people
- Sponsor
- Celgene
B-cell Malignancy, Marginal Zone Lymphoma
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion…
- Conditions
- B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- CaDAnCe-101 (NCT05006716)
- Testing
- Tacabrutideg
- Where
- 114 sites in United States, Australia and 14 more
- Volunteers
- 689 people
- Sponsor
- BeOne Medicines
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .
This is a phase Ib/II clinical trial to evaluate the safety and efficacy of TQB3909 tablets in patients with recurrent or refractory CLL/SLL.
- Trial name
- NCT05959694
- Testing
- TQB3909 tablet
- Where
- 25 sites in China
- Volunteers
- 107 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Lymphocytic Leukemia (CLL)
Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)
To evaluate the effectiveness and safety of forodesine in CLL patients
- Trial name
- NCT00640523
- Testing
- forodesine HCl
- Where
- 11 sites in United States, Australia
- Volunteers
- 23 people
- Sponsor
- BioCryst Pharmaceuticals
Non-hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies
ZX-101A-101 is a Phase 1/2a, first-in-human, open-label, multicenter, multiple-ascending dose study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamic, and preliminary antitumor activity of ZX-101A…
- Conditions
- Non-hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT04504708
- Testing
- ZX-101A
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Hangzhou Zenshine Pharmaceuticals Co., Ltd.
Glioblastoma Multiforme
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)
- Trial name
- NCT02586857
- Testing
- ACP-196
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Acerta Pharma BV
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
The purpose of this single-arm, open-label, Phase 1b/2a, multicenter basket study is to evaluate whether tafasitamab and parsaclisib can be safely combined at the recommended Phase 2 dose (RP2D) and dosing regimen that was…
- Trial name
- topMIND (NCT04809467)
- Testing
- tafasitamab, parsaclisib
- Where
- 50 sites in United States, Austria and 5 more
- Volunteers
- 54 people
- Sponsor
- Incyte Corporation
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one…
- Trial name
- BRUIN CLL-322 (NCT04965493)
- Testing
- Pirtobrutinib, Venetoclax, Rituximab
- Where
- 176 sites in United States, Australia and 21 more
- Volunteers
- 600 people
- Sponsor
- Loxo Oncology, Inc.